XSPRAY Stock Overview
A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Xspray Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 50.80 |
| 52 Week High | SEK 91.70 |
| 52 Week Low | SEK 28.70 |
| Beta | 0.99 |
| 11 Month Change | -36.34% |
| 3 Month Change | 24.05% |
| 1 Year Change | 44.32% |
| 33 Year Change | -60.92% |
| 5 Year Change | -25.84% |
| Change since IPO | 61.78% |
Recent News & Updates
Recent updates
We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully
Feb 25
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
May 11We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth
Feb 01We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
Oct 26We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
Jun 20We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely
Mar 19Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?
Feb 12Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation
Dec 04
Shareholder Returns
| XSPRAY | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -41.9% | -5.7% | 1.0% |
| 1Y | 44.3% | 20.5% | 18.4% |
Return vs Industry: XSPRAY exceeded the Swedish Biotechs industry which returned 17.4% over the past year.
Return vs Market: XSPRAY exceeded the Swedish Market which returned 14.5% over the past year.
Price Volatility
| XSPRAY volatility | |
|---|---|
| XSPRAY Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: XSPRAY's share price has been volatile over the past 3 months.
Volatility Over Time: XSPRAY's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 26 | Per Andersson | www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.
Xspray Pharma AB (publ) Fundamentals Summary
| XSPRAY fundamental statistics | |
|---|---|
| Market cap | SEK 1.72b |
| Earnings (TTM) | -SEK 212.58m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.1x
P/E RatioIs XSPRAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XSPRAY income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 212.58m |
| Earnings | -SEK 212.58m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 07, 2024
| Earnings per share (EPS) | -6.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XSPRAY perform over the long term?
See historical performance and comparison